2023
The Value-of-Information and Value-of-Implementation from Clinical Trials of Diagnostic Tests for HIV-Associated Tuberculosis: A Modeling Analysis
Pei P, Fitzmaurice K, Le M, Panella C, Jones M, Pandya A, Horsburgh C, Freedberg K, Weinstein M, Paltiel A, Reddy K. The Value-of-Information and Value-of-Implementation from Clinical Trials of Diagnostic Tests for HIV-Associated Tuberculosis: A Modeling Analysis. MDM Policy & Practice 2023, 8: 23814683231198873. PMID: 37743931, PMCID: PMC10517616, DOI: 10.1177/23814683231198873.Peer-Reviewed Original ResearchIncremental net monetary benefitOptimal decisionsOptimal strategyNet monetary benefitDecision makers' willingnessHealth economic standpointSputum XpertClinical trialsEconomic outcomesHigh VOTMonetary benefitsNew clinical trial evidenceDiagnostic testsHIV-Associated TuberculosisEconomic standpointClinical trial evidenceVOI analysisPublic health decision makingValue of trialsDownstream health outcomesSouth AfricaEvaluation of trialsHealth decision makingWillingnessDecisions
2022
Population-Level Strategies for Nirmatrelvir/Ritonavir Prescribing—A Cost-effectiveness Analysis
Savinkina A, Paltiel A, Ross J, Gonsalves G. Population-Level Strategies for Nirmatrelvir/Ritonavir Prescribing—A Cost-effectiveness Analysis. Open Forum Infectious Diseases 2022, 9: ofac637. PMID: 36589482, PMCID: PMC9792084, DOI: 10.1093/ofid/ofac637.Peer-Reviewed Original ResearchCost-effectiveness analysisTrade-offs implicitSevere diseaseDecision analytic modelAllocation decisionsPay thresholdsPolicy strategiesUnvaccinated patientsVaccination statusHigh riskTreatment effectivenessHigh-risk individualsAllocation strategyPopulation-level strategiesWillingnessFurther priorityDrug costsSensitivity analysisCostRitonavir treatmentUnvaccinated personsVaccinated adultsPatient populationClinical trialsLower risk
2017
Cost-effectiveness analysis of typhoid conjugate vaccines in five endemic low- and middle-income settings
Antillón M, Bilcke J, Paltiel AD, Pitzer VE. Cost-effectiveness analysis of typhoid conjugate vaccines in five endemic low- and middle-income settings. Vaccine 2017, 35: 3506-3514. PMID: 28527687, PMCID: PMC5462484, DOI: 10.1016/j.vaccine.2017.05.001.Peer-Reviewed Original ResearchConceptsRoutine infant vaccinationCost-effectiveness analysisOptimal strategyHealthcare payer perspectiveVaccine priceOne-time catchMiddle-income countriesIntervention costsPayer perspectiveInfant vaccinationDong ThapRoutine vaccinationMiddle-income settingsTyphoid transmissionRate of hospitalizationNumber of dosesDynamic modelPricesWorld Health OrganizationInvestmentLwakReturnWillingnessTyphoid feverVaccination
2014
Cost-effectiveness of canine vaccination to prevent human rabies in rural Tanzania.
Fitzpatrick MC, Hampson K, Cleaveland S, Mzimbiri I, Lankester F, Lembo T, Meyers LA, Paltiel AD, Galvani AP. Cost-effectiveness of canine vaccination to prevent human rabies in rural Tanzania. Annals Of Internal Medicine 2014, 160: 91-100. PMID: 24592494, PMCID: PMC4084874, DOI: 10.7326/m13-0542.Peer-Reviewed Original ResearchConceptsVaccination campaignCanine vaccinationPrompt postexposure prophylaxisBase-case analysisVaccination coverageHuman rabiesSocietal willingnessProbability-based evaluationU.S. dollarsEconomic outcomesContact-tracing studiesEmpirical uncertaintyRural AfricaRural TanzaniaOptimal vaccination coverageOngoing vaccination campaignRabies vaccination campaignsGreat uncertaintyAnnual mortality ratePostexposure prophylaxisEpidemiologic variablesTransmission of rabiesHealth burdenWillingnessMortality rate